BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China.
- BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China.
- During the clinical development stage, BioNTech will provide the clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.
- If the vaccine receives marketing authorization in China, Fosun Pharma will exclusively commercialize the vaccine in Mainland China, Hong Kong and Macau Special Administration Regions and in Taiwan.
- Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.